SILO
Silo Pharma, Inc.Company Information
- Company Name
- Silo Pharma, Inc.
- CIK
- CIK0001514183
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SILO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SILO
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-15
- Last sale
- —
- Shares purchased (TTM)
- 20,500
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 105,445
- Shares outstanding
- 1,098,517
- Ownership
- 9.60%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -25.47%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 4 | 5 | 4 | 4 | 3 | 4 | 5 | 5 | 3 | 4 | 0 | ||||||
| Short Term Investments | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 9 | ||||||
| Crypto Asset Fair Value Current | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Other Assets Current | - | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 6 | 7 | 7 | 6 | 6 | 6 | 7 | 8 | 8 | 7 | 8 | 9 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Noncurrent | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
Assets Noncurrent | ||||||||||||||||||
| Receivables Net Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Deferred Costs | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Intangible Assets Net Excluding Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Assets | 6 | 7 | 8 | 6 | 7 | 6 | 7 | 9 | 8 | 7 | 8 | 9 | ||||||
Liabilities Current | ||||||||||||||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | ||||||
| Accounts Payable And Accrued Liabilities Current | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Contract With Customer Liability Current | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | ||||||
| Liabilities Noncurrent | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Preferred Stock | - | - | - | - | - | - | - | - | - | - | 18 | - | ||||||
| Additional Paid In Capital | 27 | 27 | 26 | 24 | 22 | 20 | 20 | 20 | 19 | 18 | 18 | 17 | ||||||
| Treasury Stock Preferred Value | - | - | - | - | - | - | - | - | - | - | -0 | - | ||||||
| Treasury Stock Value | - | - | - | - | - | - | - | -0 | -1 | -1 | -0 | -0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -22 | -21 | -19 | -19 | -18 | -16 | -15 | -14 | -13 | -12 | -11 | -10 | ||||||
| Stockholders Equity | 5 | 6 | 6 | 5 | 5 | 4 | 5 | 7 | 6 | 5 | 6 | 7 | ||||||
| Liabilities And Stockholders Equity | 6 | 7 | 8 | 6 | 7 | 6 | 7 | 9 | 8 | 7 | 8 | 9 | ||||||
| Series C Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Interest Receivable Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Interest Receivable Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 7 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 500 | ||||||
| Treasury Stock Common Shares | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSilo Pharma, Inc. (SILO) — SEC Financial Statements & Analysis
Silo Pharma, Inc. (SILO) is a pharmaceutical preparations company, incorporated in NV. Silo Pharma, Inc. trades on Nasdaq as: SILO. Silo Pharma, Inc. (SILO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Silo Pharma, Inc. carries a market cap of $6.82M, a P/E ratio of -1.53x, a P/B ratio of 1.40x, a P/S ratio of 126.15x, an enterprise value of $3.54M, and an EV/EBITDA multiple of -0.79x. On profitability, it posts a gross margin of 11.90%, an operating margin of -8250.46%, a net margin of -8269.53%, a Return on Equity (ROE) of -91.23%, a Return on Assets (ROA) of -70.96%, and a Return on Invested Capital (ROIC) of -406.50%. Per share, it reports EPS of $-4.07, diluted EPS of $-4.07, free cash flow per share of $-3.04, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -25.00% year-over-year, net income growth of -8.65% year-over-year, and EPS growth of -65.18% year-over-year. On the balance sheet, it maintains a current ratio of 5.36x, a quick ratio of 5.10x, working capital of $4.65M, a debt-to-equity ratio of 0.22x, a debt ratio of 0.18, an interest coverage ratio of -112.03x, free cash flow of $-3.34M (TTM), and net debt of $-3.28M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.82M
- P/E TTM
- -1.53x
- EPS TTM
- $-4.07
- P/B TTM
- 1.40x
- ROE TTM
- -91.23%
- ROA TTM
- -70.96%
- Debt To Equity
- 0.22x
- Free Cash Flow TTM
- $-3.34M
- Net Revenue TTM Growth 1Y
- -25.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Silo Pharma, Inc. in?
Silo Pharma, Inc. (SILO) operates in the Pharmaceutical Preparations industry.
What exchange does SILO trade on?
Silo Pharma, Inc. (SILO) trades on the Nasdaq.
Where is Silo Pharma, Inc. incorporated?
Silo Pharma, Inc. is incorporated in NV.
When was Silo Pharma, Inc. (SILO)'s most recent SEC filing?
Silo Pharma, Inc. (SILO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is SILO's market cap?
Silo Pharma, Inc. (SILO) has a market capitalization of $6.82M as of 2026-06-30.
What is SILO's EPS (earnings per share)?
Silo Pharma, Inc. (SILO)'s trailing twelve month EPS is $-4.07 as of 2026-06-30.
What is SILO's ROE (return on equity)?
Silo Pharma, Inc. (SILO)'s trailing twelve month Return on Equity (ROE) is -91.23% as of 2026-06-30.
What is SILO's ROA (return on assets)?
Silo Pharma, Inc. (SILO)'s trailing twelve month Return on Assets (ROA) is -70.96% as of 2026-06-30.
What is SILO's ROIC (return on invested capital)?
Silo Pharma, Inc. (SILO)'s trailing twelve month Return on Invested Capital (ROIC) is -406.50% as of 2026-06-30.
What is SILO's EV/EBITDA?
Silo Pharma, Inc. (SILO)'s trailing twelve month EV/EBITDA is -0.79x as of 2026-06-30.